Mochida Pharmaceutical Co., Ltd. (4534.T) Stock
Mochida Pharmaceutical Co., Ltd.

Company profile
Mochida Pharmaceutical reported revenue of 105.16 billion JPY for fiscal year 2025, up 2.2% from fiscal year 2024, and net income of 5.69 billion JPY. That is a net profit margin of 5.4% for fiscal year 2025. Its largest business segment, Pharmaceutical, brought in 93% of segment revenue in fiscal year 2025. Our analysis of its filings shows revenue growing from 103.26 billion JPY in fiscal year 2023 to 105.16 billion JPY in fiscal year 2025, 0.9% a year on average. Mochida Pharmaceutical reports about 1,479 full-time employees.
Figures from company filings; latest fiscal year ended March 31, 2025.
About Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatologists, psychiatry, and gastroenterological, including Realda and Collagen for the treatment of ulcerative colitis; Goofis and Movicol for the treatment of chronic constipation; interstitial pulmonary hypertension for the treatment of pulmonary arterial hypertension; Treprospermid, for pulmonary hypertension associated with ulcerative lung disease; Uris, for gout and hyperuricemia; and Clorox, for ulcerative colitis; Epadel for hyperlipidemia and obstructive arteriosclerosis; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker antihypertensive drug; Heparin Na anticoagulants; and Onboard, ulcerative colitis and Crohn's disease treatment agents. In addition, it develops medical devices, including dMD-002, which is used for the treatment of cavernous nerve injury; and dMD-003 for adhesion prevention material. Further, the company engages in the development, production, distribution, sale, and marketing of skincare products, as well as academic research and marketing. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Shinjuku, Japan.
Largest shareholders
- Mochida Memorial Foundation15.63%
- Princess Takamatsu Cancer Research Foundation4.63%
- Mitsubishi Ufj Financial Group, Inc.4.36%
- Mizuho Bank Pension Fund3.94%
- Mochida Pharmaceutical Co., Ltd.3.30%
Share of the company, as of September 25, 2026
Leadership
- Naoyuki Mochida — President & Chairperson, 67
- Masaaki Yokosuka — Executive Officer and Legal & Compliance Manager
- Junichi Sakaki Ph.D. — Senior Executive Managing Officer & Representative Director, 65
- Tomokazu Matsusue — Managing Executive Officer & Head of Business Development Division
- Hitoshi Mizuno — Managing Executive Officer & GM of Medical Device Product Development
How much revenue does Mochida Pharmaceutical make?
Mochida Pharmaceutical reported 105.16 billion JPY in revenue for fiscal year 2025, up 2.2% from 102.89 billion JPY in fiscal year 2024.
What is Mochida Pharmaceutical's largest business segment?
Pharmaceutical, with 97.99 billion JPY or 93% of segment revenue in fiscal year 2025. Next: Healthcare Business (7%).
What companies are similar to Mochida Pharmaceutical?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Kissei Pharmaceutical Co., Ltd. (4547.T), Kaken Pharmaceutical Co., Ltd. (4521.T), Katakura Industries Co.,Ltd. (3001.T), Zeria Pharmaceutical Co., Ltd. (4559.T).
Company Information
Data as of .
How to cite: DataPorium, “Mochida Pharmaceutical Co., Ltd. (4534.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4534.T